MedTrace Logo

A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome

NCT05153434 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2025-05-09

No results posted yet for this study

Summary

A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of ARD-101 in Patients with Prader-Willi Syndrome

Conditions

Interventions

DRUG

ARD-101

Twice Daily, Oral Administration

Sponsors & Collaborators

  • Children's Hospital Colorado

    collaborator OTHER

  • Stanford University

    collaborator OTHER

  • Aardvark Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
17 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-27
Primary Completion
2024-09-24
Completion
2024-09-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05153434 on ClinicalTrials.gov